Today: 29 April 2026
Arista Networks stock jumps 5% as traders eye Fed week and Feb. 12 earnings

Arista Networks stock jumps 5% as traders eye Fed week and Feb. 12 earnings

NEW YORK, Jan 26, 2026, 15:51 EST — Regular session

Arista Networks shares jumped roughly 5% Monday, pushing the stock close to last week’s peak as investors swung back into tech ahead of a packed slate of market events. The stock climbed 5.4% to $143.70, hitting an intraday high of $146.40.

U.S. stocks edged higher ahead of key tech earnings and the Federal Reserve’s policy announcement on Wednesday, fueling a tug-of-war around megacap and AI-focused names that’s been playing out for weeks. “Communications and technology sectors are performing strongly today,” noted Chris Zaccarelli, chief investment officer at Northlight Asset Management. Chris Larkin from E*Trade added that Wednesday’s Fed decision “will likely keep politics in the headlines.” Reuters

This hits home for Arista since traders frequently use the network gear maker as a gauge for data-center demand. When doubts arise over AI spending translating into profits, cloud buildout suppliers can see sharp moves—often without any new company updates.

Options activity pushed Arista into focus for some traders early on. TheFly, cited by TipRanks, highlighted Arista as a notable gainer among liquid option names; these stock options allow investors to place leveraged bets on the stock’s next move.

Arista’s upcoming key event is its quarterly earnings report. The company plans to publish results for the quarter ending Dec. 31 after the U.S. market closes on Feb. 12 and will hold a conference call that same day.

As the report approaches, investors seem set to zero in less on the recent quarter and more on the outlook for 2026 demand. They’ll also be looking for updates on order trends linked to AI clusters, along with signs that enterprise clients might be delaying refresh cycles.

Competition is fierce in high-speed switching and routing, with Arista up against major rivals and deep-pocketed challengers. If customers start dual-sourcing more or delay orders into future quarters, the stock’s outlook could shift fast.

One risk for bulls: Arista’s valuation already reflects strong execution, leaving little room for error. High-multiple infrastructure stocks can easily tank on even minor setbacks. Add a hawkish Fed surprise or disappointing big-tech guidance this week, and the broader “AI trade” could come under pressure, pulling suppliers down as well.

For now, the tape is calling the shots. Traders are set to eye the Fed on Wednesday for hints about the rate path, then shift focus to Arista’s Feb. 12 report and conference call for a clearer picture of demand.

Stock Market Today

  • Nasdaq Futures Rise Ahead of Fed Decision and Major Tech Earnings
    April 29, 2026, 9:10 AM EDT. Nasdaq futures gained 0.4% ahead of the Federal Reserve's policy decision and earnings reports from tech giants Alphabet, Microsoft, Amazon, and Meta. Markets are cautious following a broad sell-off in major indices driven by chip stock weakness linked to slowing growth at AI firm OpenAI. Investors await the Fed's stance on inflation and interest rates, with crude oil prices rising amid unresolved US-Iran tensions. The Fed is expected to hold rates steady in Jerome Powell's final meeting before his replacement, Kevin Warsh, awaits Senate approval. Key focus remains on AI capital expenditure and the potential for further rate hikes in 2024. Earnings from AbbVie, AstraZeneca, Total Energies, UBS, and GSK are also in focus.

Latest article

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
TARRYTOWN, New York, April 29, 2026, 09:02 EDT Regeneron Pharmaceuticals beat Wall Street’s first-quarter revenue and profit estimates on Wednesday, as growth in Dupixent and cancer drug Libtayo helped offset a weaker showing from its Eylea eye-drug franchise. Its shares were down 1.1% in premarket trading. The result matters now because Regeneron is trying to prove it can keep growing while its older Eylea product faces pressure from cheaper versions and rival treatments such as Roche’s Vabysmo. The company has been pushing patients toward Eylea HD, a higher-dose version meant to hold market share in retinal disease. Investors also are
Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

Humana Stock Drops After Earnings Beat: Medicare Advantage Headwind Keeps Pressure On

29 April 2026
Humana beat first-quarter profit estimates, earning $10.31 per share adjusted, but shares fell over 6% premarket after it kept its 2026 profit outlook unchanged and cut its GAAP earnings forecast. Revenue rose to $39.65 billion. The insurer cited lower Medicare Star Ratings for the earnings decline and said medical and pharmacy costs are “slightly better” than expected. Competitors Centene, UnitedHealth, and Elevance recently raised their annual forecasts.
Marvell stock climbs in New York trade as Fed week puts AI-linked chip names in play
Previous Story

Marvell stock climbs in New York trade as Fed week puts AI-linked chip names in play

Oracle stock jumps nearly 3% as TikTok U.S. tie-up comes back into focus
Next Story

Oracle stock jumps nearly 3% as TikTok U.S. tie-up comes back into focus

Go toTop